A detailed history of Simplex Trading, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 284,713 shares of RXRX stock, worth $1.97 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
284,713
Previous 94,772 200.42%
Holding current value
$1.97 Million
Previous $710,000 164.23%
% of portfolio
0.07%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$5.92 - $8.6 $1.12 Million - $1.63 Million
189,941 Added 200.42%
284,713 $1.88 Million
Q2 2024

Jul 25, 2024

BUY
$7.35 - $10.05 $430,386 - $588,487
58,556 Added 161.69%
94,772 $710,000
Q1 2024

Apr 25, 2024

BUY
$9.13 - $15.52 $330,652 - $562,072
36,216 New
36,216 $361,000
Q3 2023

Nov 01, 2023

BUY
$6.59 - $15.86 $544,946 - $1.31 Million
82,693 Added 5835.78%
84,110 $643,000
Q2 2023

Aug 04, 2023

BUY
$4.56 - $9.94 $2,252 - $4,910
494 Added 53.52%
1,417 $10,000
Q1 2023

Apr 27, 2023

SELL
$6.42 - $9.64 $3,094 - $4,646
-482 Reduced 34.31%
923 $6,000
Q4 2022

Feb 02, 2023

SELL
$7.16 - $12.7 $9,809 - $17,399
-1,370 Reduced 49.37%
1,405 $10,000
Q3 2022

Nov 04, 2022

BUY
$7.83 - $13.6 $21,728 - $37,740
2,775 New
2,775 $29,000
Q2 2022

Aug 03, 2022

SELL
$5.04 - $9.26 $2,000 - $3,676
-397 Closed
0 $0
Q1 2022

May 02, 2022

SELL
$6.16 - $18.03 $2,987 - $8,744
-485 Reduced 54.99%
397 $2,000
Q4 2021

Feb 23, 2022

SELL
$16.14 - $21.86 $98,195 - $132,996
-6,084 Reduced 87.34%
882 $15,000
Q3 2021

Oct 28, 2021

SELL
$19.03 - $41.33 $1,903 - $4,133
-100 Reduced 1.42%
6,966 $250,000
Q2 2021

Aug 12, 2021

BUY
$18.0 - $37.42 $127,188 - $264,409
7,066 New
7,066 $257,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.25B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.